News

Full steam ahead for Copaxone copies as SCOTUS denies Teva's bid for delay

Last week, generics makers asked the Supreme Court to let them launch their copies of Teva's Copaxone while it hears the Israeli company's appeal over the drug's patents. Now, they'll likely get that chance. Chief Justice John Roberts rejected Teva's bid to block competition until the court clash wraps, meaning generics could hit as soon as next month.

Gardasil dose reduction could boost EU sales for Merck-Sanofi joint venture

Now that the European Commission has officially approved a two-dose Gardasil regimen for early teens, Merck and Sanofi--who market the HPV vaccine in Europe through joint venture Sanofi Pasteur MSD--will see the number of shots per patient fall.

Novartis near to wrapping up $1.7B sale of part-owned patchmaker LTS Lohmann

It's been almost a yearlong contest, but a deal for patchmaker LTS Lohmann appears to be nearing the finish line. The private equity firm Nordic Capital is likely to beat out competitor Wendel for the deal, Bloomberg says, at a price of about $1.7 billion.

England sets aside $31M to fund Sovaldi for sickest patients

While next-gen hep C treatment Sovaldi costs $84,000 per 12-week course of treatment, it boasts a 90% cure rate--and that's convinced the U.K.'s National Health Service to spend £18.7 million to fund the treatment for England's sickest patients.

Gilead's Sovaldi, GSK's Anoro stand out in 2014's blockbuster crop, report says

Want to take a guess about which three new drugs are marked for greatness in 2014? One of them is obvious. Another, not so much. And the third isn't approved yet.

GlaxoSmithKline steps up bribery probes, eyeing potential violations in 9 Middle Eastern countries

GlaxoSmithKline has added two more countries to its bribery-investigation list. The U.K.-based drugmaker now says it faces probes in Jordan and Lebanon, in addition to recently announced investigations in Iraq and Poland.

Under fire from local pharmas, China backs off price caps

On Tuesday, the Chinese government quietly announced that it is easing up on its policy of restricting drug prices and will allow pharmaceutical companies to set prices on some medicines, according to Reuters.

Pharma's top 10 M&A deals of 2013

All things being relative, 2013 was a pretty good year for M&A in pharma. There were 169 deals valued at $76 billion last year, according to the information ninjas who dice the numbers at...

Judge halts Massachusetts governor's ban on powerful Zogenix painkiller

After last week expressing her opinion that Massachusetts Governor Deval Patrick was "out of line" with his move to block controversial superstrength painkiller Zohydro, U.S. District Court Judge Rya Zobel granted maker Zogenix's request for an injunction temporarily halting the ban.

GlaxoSmithKline's new diabetes med faces formidable GLP-1 foes

GlaxoSmithKline's albiglutide, now dubbed Tanzeum for the U.S. market, nabbed FDA approval Tuesday.

EMA warns Herceptin vials stolen in Italy spreading through EU

Vials of Roche's cancer med Herceptin that were stolen in Italy are now showing up in other places in Europe, leading the European Medicines Agency (EMA) to issue an alert and Herceptin maker Roche to recall all of the batches from which the stolen drugs came.

New report finds Bydureon safest of new class of diabetes drugs

With big money to be made, drugmakers have responded to the global rise in Type 2 diabetes with a host of new classes of treatments that work in different ways. And while that is generally a good thing, the full range of adverse effects of all of these new drugs can't be known until they have been on the market for awhile, and some will fare better than others, a new report states.

Reckitt CFO: Spinoff of pharma unit a 'strong option'

British consumer products maker Reckitt Benckiser said during a first-quarter business review today that it's moving closer to carving out its struggling pharmaceutical unit and listing it as a separate public company. A strategic review of the unit that was launched last October continues, but a "capital markets solution is emerging as a strong option," Reckitt CFO Adrian Hennah told Reuters.

Amgen's Bradway nets $13.65M in 2013, sans Onyx bonus

Amgen CEO Robert Bradway nabbed Onyx Pharmaceuticals for $10.4 billion last summer, but that wasn't enough to net him the kind of deal-related bonus some of his peers enjoy. But his take-home increased over last year's haul, which was enough to score him 13th place on the list of biopharma's highest-paid chiefs.

Generics makers ask SCOTUS to let them proceed with Copaxone copies

Teva wants generics makers to hold off on launching their copies of multiple sclerosis drug Copaxone until the Supreme Court hears its appeal in a patent fight over the drug. And unsurprisingly, those generics companies are not that into the idea.

Novartis' gain is consumers' $900M loss from stalled Ranbaxy generics

The inability of Ranbaxy Laboratories to get its generic of heart drug Diovan to market for 18 months has been a boon for Novartis. Not so much for consumers.

Boehringer Ingelheim revenue slide cushioned by Pradaxa sales jump

Pradaxa may not be leading the new-age anticoagulant market, but it's certainly leading Boehringer Ingelheim's growth efforts. The blockbuster med made significant gains in 2013 to help offset currency effects and keep operating income up in the face of dwindling sales, the company said Tuesday.

New drugs are J&J's Q1 heroes, spurring pharma giant to hike 2014 forecast

Weak consumer sales and flat medical device and diagnostics sales didn't stop Johnson & Johnson from trouncing analyst estimates Monday--or from raising its guidance for the year. A lineup of hot new meds powered the drug giant's first-quarter performance, helping pharma sales climb nearly 11% to $7.5 billion.

Novartis marks 235 admin jobs for deletion amid companywide restructuring

Novartis is ticking off another 235 boxes on its job cuts list. The Swiss drugmaker plans to lay off 215 administrative and support staff in New Jersey by the end of June, and another 20 in similar positions elsewhere in the U.S., the Star-Ledger reports.

Roche cancer drugs Perjeta and Kadcyla drive strong Q1 results

Swiss drug giant Roche has hit the ground running in 2014, announcing today that quick uptake of its new cancer drugs helped drive first-quarter sales up 5% year-over-year in constant currencies to 11.5 billion Swiss francs ($13 billion).